Atossa Therapeutics is exploring whether its experimental breast cancer therapy could also treat two rare diseases: McCune-Albright syndrome and Duchenne muscular dystrophy. These indications could offer faster, less expensive paths to market, with the added possibility of potentially lucrative priority review vouchers if the programs succeed. The company believes its endoxifen, a major active metabolite of the breast cancer drug tamoxifen, could address estrogen-driven precocious puberty in McCune-Albright syndrome and increase production of a muscle protein that could help compensate for the protein deficiency underlying Duchenne muscular dystrophy. Steven Quay, CEO of Atossa, discusses the science behind these two applications, the studies needed to test them, and the business decisions involved in expanding into rare disease.

Stay Connected
Sign up for updates straight to your inbox.
